A High-Affinity Fully Human Anti-Il-6 mAb, 1339, for the Treatment of Multiple Myeloma

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-09-1483
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Affinity Improvement of the Fully Human Anti‑TSLP Recombinant Antibody

Molecular Medicine Reports
OncologyGeneticsMolecular BiologyBiochemistryCancer ResearchMolecular Medicine
2019English

Icaritin Suppresses Multiple Myeloma, by Inhibiting IL-6/JAK2/STAT3

Oncotarget
Oncology
2015English

IL-6-induced Enhancement of C-Myc Translation in Multiple Myeloma Cells

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2010English

High Affinity Cross-Reacting mAb Generated by Minimal Mimicry: Implications for the Pathogenesis of Anti-Nuclear Autoantibodies and Immunosuppression

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
1998English

A High-Risk Signature for Patients With Multiple Myeloma Established From the Molecular Classification of Human Myeloma Cell Lines

Haematologica
Hematology
2010English

Novel Drugs for the Treatment of Multiple Myeloma

Haematologica
Hematology
2010English

Bortezomib for the Treatment of Multiple Myeloma Patients

Health Technology Assessment
MedicineHealth Policy
2009English

Osteolytic Disease in IL-6 and Myc Dependent Mouse Model of Human Myeloma

Haematologica
Hematology
2019English

A Fully Human IgG1 Anti-Pd-L1 MAb in an in Vitro Assay Enhances Antigen-Specific T-Cell Responses

Clinical and Translational Immunology
AllergyImmunologyNursing
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy